UBS Pan-European Conference “Capturing the Emerging Trend”

Hanspeter Spek, President - Global operations

June 1st, 2012

2

Forward Looking Statements

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Emerging Markets opportunity

Sanofi’s leadership

Agenda

3

Growth Contribution from Emerging Markets to Global Pharma Market Expected to be >70%

4

2010

World Pharmaceutical Market(1)

2015e

Contribution to Growth

(1) IMS Market Prognosis, 2011-2015 (2 ) World less North America (USA, Canada), Western Europe (France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg,

Portugal, Holland, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand

Emerging Markets Mature Markets

Opportunities and Challenges

● Growing and aging populations

● Shift from acute to chronic diseases

● Need for greater access to medicines

● Cost burden on governments and healthcare reforms

● Largely out-of-pocket markets

● Increased investment from all market players

Sales Split

74%

26%

€656bn

€837bn

(2)

26%

74%

64%

36%

5

Macro Factors Point to Strong Growth in Emerging Markets

(1) IMF; CIA The World Factbook (2) IMF; internal analysis (3) IMF; WHO 2008 (4) IMS Pharmerging Markets CAGR 2010-2015 (5) WHO, World Population Prospects: The 2010 revision; CIA The World Factbook (6) Brookings Institution; Goldman Sachs

Emerging Markets

Population(1) 6bn

Estimated GDP growth 2010-2015(2) 5-9%

Healthcare expenditure as % of GDP(3) 5-6%

Estimated Pharmaceutical Market growth CAGR 2010-2015(4) 13-16%

Annual birth cohorts(5) 120m

Large middle class by 2030(6) ~2bn

Emerging Markets opportunity

Sanofi’s leadership

Agenda

6

Sanofi - An Unparalleled Leadership Position in Emerging Markets

7

(1) World less North America (USA, Canada), Western Europe (France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Holland, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand

(2) Emerging Markets sales of €10,133m, up +10.1% at CER in 2011

+16%

+9%

2011

€10.1bn

2010 2009 2008 2007 2006 2005

€5.0bn

Sanofi’s Performance in Emerging Markets(1, 2)

Sanofi Sales in Emerging Markets Overtake Sales in Traditional Markets

8

Note: Sales growth excluding A/H1N1 and Genzyme is : +10.4% for Emerging Markets, -5.7% for U.S., -10.5% for Western Europe, +6.3% for ROW (1) World less North America (USA, Canada), Western Europe (France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Holland, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand (2) Emerging Markets represented 30.3% of Sanofi sales in 2011 vs. 24% in 2008 (3) Japan, Canada, Australia and New Zealand

ROW

€4,169m +13.8% at CER

Western Europe

€9,130m

-4.0% at CER

United States

€9,957m

+6.8% at CER

(3)

Emerging Markets

€10,133m

+10.1% at CER

30.3%

(1, 2)

29.8%

27.3%

12.5%

9 (1) Growth at CER excluding Genzyme and A/H1N1

Sanofi Benefits from a Broad Emerging Markets Presence and Enjoys a Strong Performance in BRIC

+18.1%

-0.4% +15.7%

+8.4%

9

Emerging Markets FY 2011 Sales Split(1)

€3,467m

+19.8% at CER excluding Genzyme and A/H1N1

BRIC (Brazil, Russia, India, China)

# #

10

Well Poised to Capture Growth in Other Fast Growing Economies

€10.1bn Total Emerging Markets Sales

in 2011

#1 in Africa and Middle East

#2 in CEE #2 in LatAm #4 in Asia

10 countries with sales between

€100m and €500m in 2010

BRIC: Brazil, Russia, India, China (1) IMS MIDAS MAT Q1 2011

~3bn

Large Population

Sanofi Leadership Position

outside BRIC(1)

Countries with Scale

BRIC 34.2%

Non-BRIC 65.8%

Sanofi is the #1 Healthcare Company in Emerging Markets

11

A commercial presence in a large number of Emerging

Markets

Sanofi’s Scorecard in Emerging Markets

Number one company in Emerging

Markets by market share

A top position in most of the fast growing economies

One of the biggest sales

forces in Emerging Markets

Largest proportion of

sales generated in Emerging

Markets among peers

A wide network of

industrial sites across

Emerging Markets

#1 with

5.4% market share (1)

#1 in BRIC

and non-BRIC

>30% of global

sales

~21,000 sales

people (2)

48 industrial

sites (2)

~100 countries with

commercial presence

(1) IMS MIDAS FY 2011 (2) December 2011 11

% of Global Product Sales in 2011

€706m

€551m

€294m

€363m

€181m

€228m

€227m

2011 Sales in Emerging Markets

Significant Contribution from Legacy Brands in Emerging Markets despite Generic Competition

Legacy Brands in Emerging Markets

€162m

12

26%

28%

32%

52%

59%

48%

35%

15%

+11.9%

+14.1%

-24.5%

+6.7%

+0.2%

+8.7%

+11.3%

2011 Sales Growth (at CER)

+9.5%

Growing Exposure to Emerging Markets with a Broad and Diversified Offering

13 (1) Merial sales not consolidated in 2008 (2) Pharmaceuticals sales excluding Diabetes, CHC and Generics

Emerging Market Sales and % Represented by Emerging Markets per Segment

Building a Tailored Portfolio in Emerging Markets through Multiple Acquisitions and Partnerships

Generics and

Consumer Health Care

● A total of 17 deals since 2008

● Addressing income disparities

● Tapping into out-of-pocket markets

● Adding local brands

● Invested a total of around €3.7bn in acquisitions

Adjusting our Offerings to Local Needs in Fast Growing Market Segments

14

15

Key Success Factors to Sustain our Unmatched Leadership Position in Emerging Markets

Historical presence

● Leverage unique accumulated experience and diversified product portfolio

Market reach ● Expand sales forces to address rural areas

Manufacturing capacity ● Grow network of industrial sites to serve increasing volume

Quality of management ● Attract, train and retain local management talent

Tapping into local innovation ● Broaden R&D networks in Asia

Bolt-on acquisitions

● Continue to enlarge our portfolio by successfully identifying and integrating M&A targets